MX2023005570A - Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion. - Google Patents
Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion.Info
- Publication number
- MX2023005570A MX2023005570A MX2023005570A MX2023005570A MX2023005570A MX 2023005570 A MX2023005570 A MX 2023005570A MX 2023005570 A MX2023005570 A MX 2023005570A MX 2023005570 A MX2023005570 A MX 2023005570A MX 2023005570 A MX2023005570 A MX 2023005570A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- cov
- sars
- receptor
- binding domain
- Prior art date
Links
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 title abstract 3
- 108020003175 receptors Proteins 0.000 title abstract 3
- 102000005962 receptors Human genes 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012636 effector Substances 0.000 abstract 2
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 abstract 1
- 229940022962 COVID-19 vaccine Drugs 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Las vacunas de SARS-CoV-2 serán esenciales para reducir la morbilidad y mortalidad; los inventores produjeron un anticuerpo que se dirige contra un antígeno de superficie (es decir CD40) de una célula que presenta un antígeno (es decir célula dendrítica) en donde la cadena pesada se conjugó al dominio de unión al receptor de la proteína de la espícula del Sars-Cov-2 para su uso como vacuna; en particular, los inventores muestran que dicha vacuna induce linfocitos B hu que secretan AB circulante, produce linfocitos B hu IgG+ específicos de S, produce la expansión de linfocitos T hu CD4+ de memoria centrales y el surgimiento de linfocitos T CD4+ de memoria efectores, produce la expansión de linfocitos T hu CD8+ de memoria centrales y el surgimiento de linfocitos T CD8+ de memoria efectores y finalmente induce linfocitos T CD8+ hu de memoria de tipo células madre; la presente invención así se refiere a anticuerpos que están dirigidos contra un antígeno de superficie de una célula que presenta un antígeno en donde la cadena pesada y/o la cadena ligera se conjuga o fusiona al dominio de unión al receptor de la proteína de la espícula del Sars-Cov-2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20306370 | 2020-11-12 | ||
EP21305091 | 2021-01-26 | ||
PCT/EP2021/081303 WO2022101302A1 (en) | 2020-11-12 | 2021-11-10 | Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023005570A true MX2023005570A (es) | 2023-05-29 |
Family
ID=78599029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023005570A MX2023005570A (es) | 2020-11-12 | 2021-11-10 | Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion. |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240010739A1 (es) |
EP (1) | EP4244253A1 (es) |
JP (1) | JP2023554587A (es) |
KR (1) | KR20230107260A (es) |
CA (1) | CA3200878A1 (es) |
CO (1) | CO2023007284A2 (es) |
MX (1) | MX2023005570A (es) |
WO (1) | WO2022101302A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU20210070A7 (es) * | 2021-08-20 | 2023-03-07 | Ct Ingenieria Genetica Biotecnologia | Antígenos quiméricos para el control de coronavirus y composiciones que los comprenden |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
AU6248994A (en) | 1993-02-22 | 1994-09-14 | Rockefeller University, The | Production of high titer helper-free retroviruses by transient transfection |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
EP1576014B1 (en) | 2002-12-23 | 2011-06-29 | Wyeth LLC | Antibodies against pd-1 and uses thereof |
KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
CA2715042C (en) | 2007-02-02 | 2021-02-02 | Baylor Research Institute | Multivariable antigens complexed with targeting humanized monoclonal antibody |
CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
KR101548143B1 (ko) | 2008-07-16 | 2015-08-28 | 베일러 리서치 인스티튜트 | 극대화된 Gag 및 Nef를 수지상 세포에 표적화시킴을 기본으로 하는 HIV 백신 |
CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
PL2350129T3 (pl) | 2008-08-25 | 2015-12-31 | Amplimmune Inc | Kompozycje antagonistów PD-1 i sposoby stosowania |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
JP5986382B2 (ja) | 2009-03-10 | 2016-09-06 | ベイラー リサーチ インスティテュートBaylor Research Institute | 抗原提示細胞ターゲティング癌ワクチン |
US8345509B2 (en) | 2009-04-16 | 2013-01-01 | Chevron U.S.A., Inc. | System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole |
CN102711824A (zh) | 2009-09-14 | 2012-10-03 | 贝勒研究院 | 针对朗格汉斯细胞的疫苗 |
WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
TWI506035B (zh) | 2010-08-13 | 2015-11-01 | Baylor Res Inst | 以直接針對抗原呈現細胞之抗體的標靶佐劑為主之新穎疫苗佐劑 |
JP6105477B2 (ja) | 2010-11-05 | 2017-03-29 | ライナット ニューロサイエンス コーポレイション | 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法 |
CA2856895C (en) | 2011-11-28 | 2021-10-26 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
KR20160081898A (ko) | 2013-09-06 | 2016-07-08 | 오리진 디스커버리 테크놀로지스 리미티드 | 면역조절제로서 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 유도체 |
SG11201601682RA (en) | 2013-09-06 | 2016-04-28 | Aurigene Discovery Tech Ltd | 1,2,4-oxadiazole derivatives as immunomodulators |
US10610585B2 (en) * | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
CN111217917B (zh) * | 2020-02-26 | 2020-10-23 | 康希诺生物股份公司 | 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法 |
CN111533809A (zh) * | 2020-04-21 | 2020-08-14 | 中国科学院武汉病毒研究所 | 针对新型冠状病毒的亚单位疫苗及应用 |
-
2021
- 2021-11-10 EP EP21806276.8A patent/EP4244253A1/en active Pending
- 2021-11-10 JP JP2023528270A patent/JP2023554587A/ja active Pending
- 2021-11-10 US US18/036,237 patent/US20240010739A1/en active Pending
- 2021-11-10 KR KR1020237017668A patent/KR20230107260A/ko unknown
- 2021-11-10 WO PCT/EP2021/081303 patent/WO2022101302A1/en active Application Filing
- 2021-11-10 CA CA3200878A patent/CA3200878A1/en active Pending
- 2021-11-10 MX MX2023005570A patent/MX2023005570A/es unknown
-
2023
- 2023-06-01 CO CONC2023/0007284A patent/CO2023007284A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023554587A (ja) | 2023-12-28 |
US20240010739A1 (en) | 2024-01-11 |
KR20230107260A (ko) | 2023-07-14 |
CO2023007284A2 (es) | 2023-07-10 |
EP4244253A1 (en) | 2023-09-20 |
WO2022101302A1 (en) | 2022-05-19 |
CA3200878A1 (en) | 2022-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061071L (no) | Kimeriske antigener for a odelegge vertstoleranse mot fremmede antigener | |
CO2020001491A2 (es) | Molécula de polipéptido con especificidad dual mejorada | |
CR20200460A (es) | Suministro intracelular de biomeléculas para modificar respuestas inmunes | |
PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
EA201992469A1 (ru) | Антигенспецифические иммунные эффекторные клетки | |
PH12020551437A1 (en) | Methods for treating hpv-associated diseases | |
MX2021007446A (es) | Epítopos artificiales promiscuos de linfocitos t colaboradores como estimuladores inmunes para inmunógenos peptídicos sintéticos. | |
DK1198250T3 (da) | FC-fusionsproteiner til forstærkning af protein- og peptidantigeners immunogenicitet | |
MXPA05013973A (es) | Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos. | |
SG158154A1 (en) | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes | |
MX2023005570A (es) | Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion. | |
EA200702180A1 (ru) | Способы лечения иммунных нарушений, связанных с пересадкой трансплантата, растворимым мутантным ctla4 | |
WO2006095330A3 (en) | Methods and immunogenic cell preparations for treating antigen-associated diseases | |
WO2007016340A3 (en) | Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response | |
BR112022000854A2 (pt) | Conjugados anticorpo - agonista de sting e seu uso em imunoterapia | |
ECSP22038109A (es) | Prote?na portadora mutante sitio dirigida y su uso en la preparaci?n de la vacuna | |
ZA202109878B (en) | A kind of abienol-based hapten, artificial antigen and antibody as well as the preparation methods and applications thereof | |
EA200900738A1 (ru) | Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1 | |
WO2010042919A3 (en) | Method of making a vaccine | |
WO2022120370A3 (en) | Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy | |
RU2010129770A (ru) | Вакцина против гриппа и способ ее получения | |
MX2020011733A (es) | Epítopos de células t cooperadoras promiscuos artificiales que facilitan la producción de anticuerpos diana con respuesta inflamatoria de células t limitada. | |
AR112228A1 (es) | Molécula de polipéptido con especificidad dual mejorada | |
CN204066550U (zh) | 火炬点火实验器 | |
WO2023250433A3 (en) | Engineered human t cells comprising a switchable chimeric antigen cell surface receptor and methods for generating them |